US Patent Allowed for NOD Tech

SHANGHAI, November 24 - NOD Pharmaceuticals Inc. announced the US Patent & Trademark Office (PTO)
has allowed the patent application for its nano-particle oral delivery or NOD
technology.

NOD technology is a highly efficient approach to incorporate peptides or
proteins into bio-adhesive nano-particles to enable oral delivery of drugs
otherwise administered as injections. NOD technology is a platform technology
that can be applied to many macromolecular drugs such as insulin, interferon,
growth hormone, exenatide, heparin and more.

Currently, an oral insulin formulation, the first candidate developed
with NOD technology, is entering phase I clinical studies in China.

"Patent allowance for NOD technology is a major step forward for NOD",
quoted from William Lee, CEO. "With this patent, and in combination with
others, NOD is building a solid foundation for its intellectual property and
core competence."

    For more information, please contact:

     William Lee, Ph.D., CEO
     Phone: +86-21-6194-0758
     Email: info@nodpharm.com

Notes for Editors

About NOD Pharmaceuticals

NOD Pharmaceuticals, Inc. is a development stage biotech company and
emerging leader in innovative delivery for biopharmaceuticals. NOD uses
patented platform technology, nano-particle oral delivery or NOD technology,
to develop oral formulations for biopharmaceuticals, including insulin,
exenatide, interferon, human growth hormone and more.

More information can be found at www.nodpharm.com .

William Lee, Ph.D., CEO, +86-21-6194-0758, or info at biolaxy.com